{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:40:46Z","timestamp":1790311246463,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune reactivity to self-antigens in both cancer and autoimmune diseases can be enhanced by systemic immune modulation, posing a challenge in cancer immunotherapy. To distinguish the genetic and immune regulation of tumor immunity versus autoimmunity, immune responses to human ErbB-2 (Her-2) and mouse thyroglobulin (mTg) were tested in transgenic mice expressing Her-2 that is overexpressed in several cancers, and HLA-DRB1*0301 (DR3) that is associated with susceptibility to several human autoimmune diseases, as well as experimental autoimmune thyroiditis (EAT). To induce Her-2 response, mice were electrovaccinated with pE2TM and pGM-CSF encoding the extracellular and transmembrane domains of Her-2 and the murine granulocyte macrophage colony-stimulating factor, respectively. To induce EAT, mice received mTg i.v. with or without lipopolysaccharide. Depletion of regulatory T cells (Treg) with anti-CD25 monoclonal antibody enhanced immune reactivity to Her-2 as well as mTg, showing control of both Her-2 and mTg responses by Treg. When immunized with, Her-2xDR3 and B6xDR3 mice expressing H2bxDR3 haplotype developed more profound mTg response and thyroid pathology than Her-2 or B6 mice that expressed the EAT-resistant H2b haplotype. In Her-2xDR3 mice, the response to mTg was further amplified when mice were also immunized with pE2TM and pGM-CSF. On the contrary, Her-2 reactivity was comparable whether mice expressed DR3 or not. Therefore, induction of Her-2 immunity was independent of DR3 but development of EAT was dictated by this allele, whereas Tregs control the responses to both self-antigens. These results warrant close monitoring of autoimmunity during cancer immunotherapy, particularly in patients with susceptible MHC class II alleles. [Cancer Res 2007;67(14):7020\u20137]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4755","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T19:07:57Z","timestamp":1184699277000},"page":"7020-7027","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells"],"prefix":"10.1158","volume":"67","author":[{"given":"Jennifer B.","family":"Jacob","sequence":"first","affiliation":[{"name":"1Karmanos Cancer Institute,"},{"name":"2Department of Immunology and Microbiology, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-chi M.","family":"Kong","sequence":"additional","affiliation":[{"name":"1Karmanos Cancer Institute,"},{"name":"2Department of Immunology and Microbiology, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chady","family":"Meroueh","sequence":"additional","affiliation":[{"name":"4Department of Pathology, St. John Hospital and Medical Center, Detroit, Michigan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Snower","sequence":"additional","affiliation":[{"name":"4Department of Pathology, St. John Hospital and Medical Center, Detroit, Michigan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chella S.","family":"David","sequence":"additional","affiliation":[{"name":"5Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Shih","family":"Ho","sequence":"additional","affiliation":[{"name":"3Institute of Environmental Health, Wayne State University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zen","family":"Wei","sequence":"additional","affiliation":[{"name":"1Karmanos Cancer Institute,"},{"name":"2Department of Immunology and Microbiology, School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,7,17]]},"reference":[{"key":"2022061623333628900_B1","doi-asserted-by":"crossref","unstructured":"Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem\u20082001; 276: 37672\u20139.","DOI":"10.1074\/jbc.M104521200"},{"key":"2022061623333628900_B2","doi-asserted-by":"crossref","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science\u20082003; 299: 1057\u201361.","DOI":"10.1126\/science.1079490"},{"key":"2022061623333628900_B3","doi-asserted-by":"crossref","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol\u20082003; 4: 330\u20136.","DOI":"10.1038\/ni904"},{"key":"2022061623333628900_B4","doi-asserted-by":"crossref","unstructured":"Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol\u20082003; 4: 337\u201342.","DOI":"10.1038\/ni909"},{"key":"2022061623333628900_B5","doi-asserted-by":"crossref","unstructured":"Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol\u20082002; 3: 135\u201342.","DOI":"10.1038\/ni759"},{"key":"2022061623333628900_B6","doi-asserted-by":"crossref","unstructured":"Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med\u20082003; 197: 403\u201311.","DOI":"10.1084\/jem.20021633"},{"key":"2022061623333628900_B7","doi-asserted-by":"crossref","unstructured":"Wei WZ, Jacob JB, Zielinski JF, et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res\u20082005; 65: 8471\u20138.","DOI":"10.1158\/0008-5472.CAN-05-0934"},{"key":"2022061623333628900_B8","doi-asserted-by":"crossref","unstructured":"Wei WZ, Morris GP, Kong YM. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother\u20082004; 53: 73\u20138.","DOI":"10.1007\/s00262-003-0444-1"},{"key":"2022061623333628900_B9","doi-asserted-by":"crossref","unstructured":"Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest\u20082005; 115: 3623\u201333.","DOI":"10.1172\/JCI25947"},{"key":"2022061623333628900_B10","doi-asserted-by":"crossref","unstructured":"Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol\u20082006; 177: 84\u201391.","DOI":"10.4049\/jimmunol.177.1.84"},{"key":"2022061623333628900_B11","doi-asserted-by":"crossref","unstructured":"Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity\u20082005; 22: 329\u201341.","DOI":"10.1016\/j.immuni.2005.01.016"},{"key":"2022061623333628900_B12","doi-asserted-by":"crossref","unstructured":"Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A\u20082005; 102: 5126\u201331.","DOI":"10.1073\/pnas.0501701102"},{"key":"2022061623333628900_B13","doi-asserted-by":"crossref","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol\u20082005; 6: 345\u201352.","DOI":"10.1038\/ni1178"},{"key":"2022061623333628900_B14","doi-asserted-by":"crossref","unstructured":"Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med\u20082006; 354: 709\u201318.","DOI":"10.1056\/NEJMoa053007"},{"key":"2022061623333628900_B15","doi-asserted-by":"crossref","unstructured":"McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol\u20082003; 23: 62\u201372.","DOI":"10.1023\/A:1021904432489"},{"key":"2022061623333628900_B16","doi-asserted-by":"crossref","unstructured":"Takamatsu J, Yoshida S, Yokozawa T, et al. Correlation of antithyroglobulin and antithyroid-peroxidase antibody profiles with clinical and ultrasound characteristics of chronic thyroiditis. Thyroid\u20081998; 8: 1101\u20136.","DOI":"10.1089\/thy.1998.8.1101"},{"key":"2022061623333628900_B17","unstructured":"Huang W, Kukes GD. Hashimoto's thyroiditis: an organ-specific autoimmune disease\u2014pathogenesis and recent developments. Lab Invest\u20081999; 79: 1175\u201380."},{"key":"2022061623333628900_B18","doi-asserted-by":"crossref","unstructured":"Canonica GW, Cosulich ME, Croci R, et al. Thyroglobulin-induced T-cell in vitro proliferation in Hashimoto's thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. Clin Immunol Immunopathol\u20081984; 32: 132\u201341.","DOI":"10.1016\/0090-1229(84)90115-6"},{"key":"2022061623333628900_B19","doi-asserted-by":"crossref","unstructured":"Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A\u20082003; 100: 8372\u20137.","DOI":"10.1073\/pnas.1533209100"},{"key":"2022061623333628900_B20","doi-asserted-by":"crossref","unstructured":"Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother\u20082005; 28: 593\u20138.","DOI":"10.1097\/01.cji.0000178913.41256.06"},{"key":"2022061623333628900_B21","doi-asserted-by":"crossref","unstructured":"Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol\u20082005; 175: 7746\u201354.","DOI":"10.4049\/jimmunol.175.11.7746"},{"key":"2022061623333628900_B22","doi-asserted-by":"crossref","unstructured":"Vaidya B, Kendall-Taylor P, Pearce SHS. Genetics of endocrine disease: the genetics of autoimmune thyroid disease. J Clin Endocrinol Metab\u20082002; 87: 5385\u201397.","DOI":"10.1210\/jc.2002-020492"},{"key":"2022061623333628900_B23","doi-asserted-by":"crossref","unstructured":"Kong YM, Lomo LC, Motte RW, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med\u20081996; 184: 1167\u201372.","DOI":"10.1084\/jem.184.3.1167"},{"key":"2022061623333628900_B24","doi-asserted-by":"crossref","unstructured":"Vladutiu AO, Rose NR. Autoimmune murine thyroiditis: relation to histocompatibility (H-2) type. Science\u20081971; 174: 1137\u20139.","DOI":"10.1126\/science.174.4014.1137"},{"key":"2022061623333628900_B25","doi-asserted-by":"crossref","unstructured":"Esquivel PS, Rose NR, Kong YM. Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide. J Exp Med\u20081977; 145: 1250\u201363.","DOI":"10.1084\/jem.145.5.1250"},{"key":"2022061623333628900_B26","doi-asserted-by":"crossref","unstructured":"Elrehewy M, Kong YM, Giraldo AA, Rose NR. Syngeneic thyroglobulin is immunogenic in good responder mice. Eur J Immunol\u20081981; 11: 146\u201351.","DOI":"10.1002\/eji.1830110216"},{"key":"2022061623333628900_B27","doi-asserted-by":"crossref","unstructured":"Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol\u20082003; 171: 5787\u201394.","DOI":"10.4049\/jimmunol.171.11.5787"},{"key":"2022061623333628900_B28","doi-asserted-by":"crossref","unstructured":"Strauss G, Vignali DA, Schonrich G, Hammerling GJ. Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics\u20081994; 40: 104\u20138.","DOI":"10.1007\/BF00188172"},{"key":"2022061623333628900_B29","doi-asserted-by":"crossref","unstructured":"Miller F, Jones RF, Jacob J, Kong YM, Wei WZ. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis\u20082004; 20: 43\u201351.","DOI":"10.3233\/BD-2004-20106"},{"key":"2022061623333628900_B30","doi-asserted-by":"crossref","unstructured":"Jacob J, Radkevich O, Forni G, et al. Activity of DNA vaccines encoding self or heterologous Her-2\/neu in Her-2 or neu transgenic mice. Cell Immunol\u20082006; 240: 96\u2013106.","DOI":"10.1016\/j.cellimm.2006.07.002"},{"key":"2022061623333628900_B31","unstructured":"Lin KY, Guarnieri FG, Stavely-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res\u20081996; 56: 21\u201336."},{"key":"2022061623333628900_B32","doi-asserted-by":"crossref","unstructured":"Wei WZ, Shi WP, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer\u20081999; 81: 748\u201354.","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6"},{"key":"2022061623333628900_B33","doi-asserted-by":"crossref","unstructured":"Piechocki MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods\u20082002; 259: 33\u201342.","DOI":"10.1016\/S0022-1759(01)00487-2"},{"key":"2022061623333628900_B34","doi-asserted-by":"crossref","unstructured":"Kong YM, David CS, Giraldo AA, Elrehewy M, Rose NR. Regulation of autoimmune response to mouse thyroglobulin: influence of H-2D-end genes. J Immunol\u20081979; 123: 15\u20138.","DOI":"10.4049\/jimmunol.123.1.15"},{"key":"2022061623333628900_B35","unstructured":"Kong YM. Experimental autoimmune thyroiditis in the mouse. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: John Wiley & Sons, Inc.; 1996."},{"key":"2022061623333628900_B36","doi-asserted-by":"crossref","unstructured":"Zhang W, Flynn JC, Kong YM. IL-12 prevents tolerance induction with mouse thyroglobulin by priming pathogenic T cells in experimental autoimmune thyroiditis: role of IFN-\u03b3 and the costimulatory molecules CD40l and CD28. Cell Immunol\u20082001; 208: 52\u201361.","DOI":"10.1006\/cimm.2001.1767"},{"key":"2022061623333628900_B37","doi-asserted-by":"crossref","unstructured":"Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol\u20081998; 10: 690\u20136.","DOI":"10.1016\/S0952-7915(98)80090-3"},{"key":"2022061623333628900_B38","doi-asserted-by":"crossref","unstructured":"Gregersen JW, Holmes S, Fugger L. Humanized animal models for autoimmune diseases. Tissue Antigens\u20082004; 63: 383\u201394.","DOI":"10.1111\/j.0001-2815.2004.00243.x"},{"key":"2022061623333628900_B39","doi-asserted-by":"crossref","unstructured":"Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol\u20082004; 3: 104\u201310.","DOI":"10.1016\/S1474-4422(03)00663-X"},{"key":"2022061623333628900_B40","doi-asserted-by":"crossref","unstructured":"Taneja V, David CS. HLA class II transgenic mice as models of human diseases. Immunol Rev\u20081999; 169: 67\u201379.","DOI":"10.1111\/j.1600-065X.1999.tb01307.x"},{"key":"2022061623333628900_B41","doi-asserted-by":"crossref","unstructured":"de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun\u20082005; 25 Suppl: 21\u20135.","DOI":"10.1016\/j.jaut.2005.09.005"},{"key":"2022061623333628900_B42","doi-asserted-by":"crossref","unstructured":"Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A\u20082006; 103: 14074\u20139.","DOI":"10.1073\/pnas.0606349103"},{"key":"2022061623333628900_B43","doi-asserted-by":"crossref","unstructured":"Morris GP, Chen L, Kong YM. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol\u20082003; 226: 20\u20139.","DOI":"10.1016\/j.cellimm.2003.11.002"},{"key":"2022061623333628900_B44","doi-asserted-by":"crossref","unstructured":"Attia P, Powell DJ, Jr., Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother\u20082006; 29: 208\u201314.","DOI":"10.1097\/01.cji.0000187959.45803.0c"},{"key":"2022061623333628900_B45","doi-asserted-by":"crossref","unstructured":"Sugihara S, Izumi Y, Yoshioka T, et al. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. J Immunol\u20081988; 141: 105\u201313.","DOI":"10.4049\/jimmunol.141.1.105"},{"key":"2022061623333628900_B46","doi-asserted-by":"crossref","unstructured":"Flynn JC, Conaway DH, Cobbold S, Waldmann H, Kong YM. Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. Cell Immunol\u20081989; 122: 377\u201390.","DOI":"10.1016\/0008-8749(89)90085-3"},{"key":"2022061623333628900_B47","unstructured":"Kong YM, Waldmann H, Cobbold S, Giraldo AA, Fuller BE, Simon LL. Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells. Clin Exp Immunol\u20081989; 77: 428\u201333."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/7020\/2570783\/7020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/14\/7020\/2570783\/7020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T07:56:07Z","timestamp":1683964567000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/14\/7020\/533250\/Control-of-Her-2-Tumor-Immunity-and-Thyroid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":47,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2007,7,17]]},"published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4755","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495902","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495902.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22368311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22368311.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}